LTCI HAS ARRIVED

TREATMENT AID FORFeLV / FIV

INFECTIONS

LTCI Indications

LTCI is an approved treatment aid for cats infected with Feline LeukemiaVirus (FeLV) and/or Feline Immuno-deficiency Virus (FIV) and the associatedsymptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia,and thrombocytopenia.

Lymphocyte T-Cell Immunomodulator (LTCI)

LTCI increases the production of IL-2. IL-2 is knownto stimulate cytotoxic T-cell responses against viruses.

.LTCI has been shown toincrease IL-2 production in

the Jurkat cell line (Fig. 1).Jurkat cells are a standardcell line used to study T-cellsignaling and leukemia.

1101000

1000

0.61.21.8

48 hr. incubation24 hr. incubation

LTCI Concentration (Log)

A b s o r b a n c e ( 4 5 0 n m )

Fig. 1: IL-2 ProductionIL-2 Production

It is now accepted that T-cellsparticipate in the productionof red and white bloodcells and platelets. LTCI,a T-cell immune modula-tor, has been shown toincrease RBC counts inseverely anemic cats andincrease lymphocyte counts.

Additionally, LTCI treatment was shown to significantlyincrease platelet recovery in a chemotherapy inducedthrombocytopenia model in mice (Fig. 2).

Hematopoietic Properties

Fig. 2: LTCI Stimulated Platelet Recovery

LTCIControl

50100200300400500

05101520Days Following Treatment

P l a t e l e t C o u n t

LTCI Immunopharmacology

Lymphocyte T-Cell Immune Modulator is a potent regulator of CD-4

lymphocyte production and function and increases IL-2 production in animals.

Clients depend on safe products for their pets. Veterinarians demandsafe products for treating ill patients. LTCI has completed formal

safety testing. The homology of LTCI among mammalian species,as

well as, the absence of any observed adverse events in several

animal species, suggests that LTCI has a very low toxicity profile.

LTCI Safety DataLTCI Efficacy Data

Fig. 3: Treatment Effects of LTCI After Three Injections

p=0.003p=0.001

% i m p r o v e m e n t

0%10%20%40%30%50%60%70%80%

Clinical ScoreLymphocyte Count

LTCI Has Been Shown to:

•

Increase CD-4 lymphocyte function

•

Increase CD-4 lymphocyte numbers

•

Increase IL-2 production

•

Increase red cell counts in severely anemic cats

FeLV and FIV Field Trial

LTCI has been evaluated in FeLV and FIV symptomaticcats. In a 23 cat study, three weekly injections of LTCIsignificantly increased lymphocyte counts and increased

the quality of life as determined by clinical scores (Fig. 3).

Study summary available at

www.IMULAN.com.

Additional efficacy studies are in progress.

Long Term Data

The long-term benefits of treatment have not been

clinically established. However, several animals in thefield trial that received monthly or bimonthly injections

have remained symptom free for long periods. Two

patients in the trial also became negative for virus byPCR analysis of bone marrow aspirate.

Lymphocyte T-Cell Immunomodulator has received a conditionallicense from the United States Department of Agriculture. Additional efficacy and potency studies are in progress. LTCI ismanufactured by T-Cyte Therapeutics, Inc and is exclusivelydistributed by IMULAN BioTherapeutics.